Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

Key schizophrenia companies such as Sumitomo Pharma America, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Reviva Pharmaceuticals, Newron Pharmaceuticals, Vanda Pharmaceuticals ...

And, while not all mental health conditions are life-threatening, some of the most prevalent serious mental conditions such as schizophrenia ... Mental Health at Boehringer Ingelheim sat down ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Two thirds of people around the world struggle to access mental health support but can we economically afford to continue down this path?

Boehringer Ingelheim (BI) and Click Therapeutics have ... that will provide additional treatment options to those living with schizophrenia. The novel mobile application combines multiple ...

No individual antipsychotic was associated with better cognitive outcomes than placebo in patients with schizophrenia spectrum disorders (SSD), according to a systematic review an ...

"To date, no gold standard for the assessment of cognitive symptoms within the context of schizophrenia has ... with Angelini, Aspen, Boehringer Ingelheim, Eisai, Ekademia, Gedeon Richter, Janssen ...

A comprehensive EU-wide mental health strategy is essential to tackle the region’s growing mental health crisis. Prioritising ...